WEBThe NOR-SWITCH extension trial aimed to assess efficacy, safety and immunogenicity in patients on CT-P13 throughout the 78-week study period (maintenance group) versus …
DA:26PA:24MOZ Rank:41
Infliximab switching from reference product to biosimilar: a review of